Last reviewed · How we verify
FIMEPINOSTAT
At a glance
| Generic name | FIMEPINOSTAT |
|---|---|
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Fimepinostat in Treating Brain Tumors in Children and Young Adults (EARLY_PHASE1)
- Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease (PHASE2)
- Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FIMEPINOSTAT CI brief — competitive landscape report
- FIMEPINOSTAT updates RSS · CI watch RSS